However, subtypes, particularly the “triple-negative” breast cancer (TNBC) that lack expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 receptors (a member of the human epidermal growth factor receptor family), have been shown to be susceptible to immunotherapeutic agents that block immunosuppressive receptors [5]. This evidence concerns the gene PGR and triple-negative breast carcinoma.